134
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Determination of the Relationship Between Kobayashi, Sano, and Egami Criteria and Prevalence of Intravenous Immunoglobulin Resistance and Coronary Artery Aneurysm in Iranian Children with Kawasaki Disease

, ORCID Icon, , ORCID Icon, , ORCID Icon, , ORCID Icon & ORCID Icon show all
Pages 187-192 | Published online: 26 Aug 2020

References

  • Shiari R. Kawasaki disease; A review article. Arch Pediatr Infect Dis. 2014;2(1):154–159.
  • Kawasaki TJA. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967;16:178–222.6062087
  • Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, council on Cardiovascular Disease in the young, American Heart Association. Circulation. 2004;110(17):2747–2771.15505111
  • Dimitriades VR, Brown AG, Gedalia A. Kawasaki disease: pathophysiology, clinical manifestations, and management. Curr Rheumatol Rep. 2014;16(6):423.24744086
  • Friedman KG, Gauvreau K, Hamaoka‐Okamoto A, et al. Coronary artery aneurysms in Kawasaki disease: risk factors for progressive disease and adverse cardiac events in the US population. J Am Heart Assoc. 2016;5(9):e003289.27633390
  • McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927–e99.28356445
  • Dionne A, Le C-K, Poupart S, et al. Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection. PLoS One. 2018;13(10):e0206001.30332473
  • Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131–137.16896641
  • Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237–240.16887442
  • Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–2612.16735679
  • Hirata S, Nakamura Y, Yanagawa H. Incidence rate of recurrent Kawasaki disease and related risk factors: from the results of nationwide surveys of Kawasaki disease in Japan. Acta Paediatr. 2001;90(1):40–44.11227331
  • Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158(5):831–835.21168857
  • Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009–2010 nationwide survey. J Epidemiol. 2012;1203070303.
  • Davies S, Sutton N, Blackstock S, et al. Predicting IVIG resistance in UK Kawasaki disease. Arch Dis Child. 2015;100(4):366–368.25670405
  • Saundankar J, Yim D, Itotoh B, et al. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics. 2014;133(4):e1009–e14.24685950
  • Park HM, Lee DW, Hyun MC, Lee S. Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease. Korean J Pediatr. 2013;56(2):75.23482814